Characterization of two novel LPS-binding sites in leukocyte integrin βA domain

Kwong Fai Wong, John M. Luk, R. Holland Cheng, Lloyd B. Klickstein, Sheung Tat Fan

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Lipopolysaccharide (LPS), a bacterial endotoxin, triggers deleterious systemic inflammatory responses when released into blood circulation, causing organ dysfunction and death. In response to LPS stimulation, CD14 and toll-like receptor (TLR)-4 elicit inflammatory signaling cascades. Although leukocyte integrins (CD11b/CD18 and CD11c/CD18) were reported to bind LPS and induce NF-κB translocation, the evidence on such epitope location remains elusive. The present study aims to delineate the LPS-binding sites on the integrin CD18 antigen and to design peptide(s) as potential prophylactic and/or therapeutic agents to modulate LPS effects in activated Jurkat cells. Epitope mapping analysis using a series of CD18 truncated variants revealed two putative LPS-binding sites within the βA region (216-248 and 266-318 a.a.), which were further confirmed by point mutation studies. Inhibition assay demonstrated that the CD18-βA266-318 peptide could block LPS binding in a dosedependent manner. Our data also indicated that treatment with the CD18-peptide modulated TNF-α mRNA transcription via the NF-κB signaling pathway in LPS-activated Jurkat cells. In conclusion, we have identified two novel LPS-binding sites located at the CD18 βA domain of leukocyte integrin, and the integrin peptide βA266-318 is shown to inhibit LPS binding and subsequent inflammatory events, having therapeutic implications to cure Gram-negative endotoxemia.

Original languageEnglish (US)
Pages (from-to)3231-3239
Number of pages9
JournalFASEB Journal
Volume21
Issue number12
DOIs
StatePublished - Oct 2007

Fingerprint

integrins
Integrins
lipopolysaccharides
Lipopolysaccharides
binding sites
leukocytes
Leukocytes
Binding Sites
peptides
Peptides
Jurkat Cells
CD18 Antigens
Epitopes
Epitope Mapping
blood circulation
endotoxemia
therapeutics
Toll-Like Receptor 4
Endotoxemia
Blood Circulation

Keywords

  • Endotoxin-neutralizing peptide
  • Lipopolysaccharide
  • NF-κB
  • Prophylaxis
  • Sepsis
  • TNF-α

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology
  • Medicine(all)

Cite this

Wong, K. F., Luk, J. M., Cheng, R. H., Klickstein, L. B., & Fan, S. T. (2007). Characterization of two novel LPS-binding sites in leukocyte integrin βA domain. FASEB Journal, 21(12), 3231-3239. https://doi.org/10.1096/fj.06-7579com

Characterization of two novel LPS-binding sites in leukocyte integrin βA domain. / Wong, Kwong Fai; Luk, John M.; Cheng, R. Holland; Klickstein, Lloyd B.; Fan, Sheung Tat.

In: FASEB Journal, Vol. 21, No. 12, 10.2007, p. 3231-3239.

Research output: Contribution to journalArticle

Wong, KF, Luk, JM, Cheng, RH, Klickstein, LB & Fan, ST 2007, 'Characterization of two novel LPS-binding sites in leukocyte integrin βA domain', FASEB Journal, vol. 21, no. 12, pp. 3231-3239. https://doi.org/10.1096/fj.06-7579com
Wong, Kwong Fai ; Luk, John M. ; Cheng, R. Holland ; Klickstein, Lloyd B. ; Fan, Sheung Tat. / Characterization of two novel LPS-binding sites in leukocyte integrin βA domain. In: FASEB Journal. 2007 ; Vol. 21, No. 12. pp. 3231-3239.
@article{b1a4c383986a49cc8b0d982efef754c3,
title = "Characterization of two novel LPS-binding sites in leukocyte integrin βA domain",
abstract = "Lipopolysaccharide (LPS), a bacterial endotoxin, triggers deleterious systemic inflammatory responses when released into blood circulation, causing organ dysfunction and death. In response to LPS stimulation, CD14 and toll-like receptor (TLR)-4 elicit inflammatory signaling cascades. Although leukocyte integrins (CD11b/CD18 and CD11c/CD18) were reported to bind LPS and induce NF-κB translocation, the evidence on such epitope location remains elusive. The present study aims to delineate the LPS-binding sites on the integrin CD18 antigen and to design peptide(s) as potential prophylactic and/or therapeutic agents to modulate LPS effects in activated Jurkat cells. Epitope mapping analysis using a series of CD18 truncated variants revealed two putative LPS-binding sites within the βA region (216-248 and 266-318 a.a.), which were further confirmed by point mutation studies. Inhibition assay demonstrated that the CD18-βA266-318 peptide could block LPS binding in a dosedependent manner. Our data also indicated that treatment with the CD18-peptide modulated TNF-α mRNA transcription via the NF-κB signaling pathway in LPS-activated Jurkat cells. In conclusion, we have identified two novel LPS-binding sites located at the CD18 βA domain of leukocyte integrin, and the integrin peptide βA266-318 is shown to inhibit LPS binding and subsequent inflammatory events, having therapeutic implications to cure Gram-negative endotoxemia.",
keywords = "Endotoxin-neutralizing peptide, Lipopolysaccharide, NF-κB, Prophylaxis, Sepsis, TNF-α",
author = "Wong, {Kwong Fai} and Luk, {John M.} and Cheng, {R. Holland} and Klickstein, {Lloyd B.} and Fan, {Sheung Tat}",
year = "2007",
month = "10",
doi = "10.1096/fj.06-7579com",
language = "English (US)",
volume = "21",
pages = "3231--3239",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "12",

}

TY - JOUR

T1 - Characterization of two novel LPS-binding sites in leukocyte integrin βA domain

AU - Wong, Kwong Fai

AU - Luk, John M.

AU - Cheng, R. Holland

AU - Klickstein, Lloyd B.

AU - Fan, Sheung Tat

PY - 2007/10

Y1 - 2007/10

N2 - Lipopolysaccharide (LPS), a bacterial endotoxin, triggers deleterious systemic inflammatory responses when released into blood circulation, causing organ dysfunction and death. In response to LPS stimulation, CD14 and toll-like receptor (TLR)-4 elicit inflammatory signaling cascades. Although leukocyte integrins (CD11b/CD18 and CD11c/CD18) were reported to bind LPS and induce NF-κB translocation, the evidence on such epitope location remains elusive. The present study aims to delineate the LPS-binding sites on the integrin CD18 antigen and to design peptide(s) as potential prophylactic and/or therapeutic agents to modulate LPS effects in activated Jurkat cells. Epitope mapping analysis using a series of CD18 truncated variants revealed two putative LPS-binding sites within the βA region (216-248 and 266-318 a.a.), which were further confirmed by point mutation studies. Inhibition assay demonstrated that the CD18-βA266-318 peptide could block LPS binding in a dosedependent manner. Our data also indicated that treatment with the CD18-peptide modulated TNF-α mRNA transcription via the NF-κB signaling pathway in LPS-activated Jurkat cells. In conclusion, we have identified two novel LPS-binding sites located at the CD18 βA domain of leukocyte integrin, and the integrin peptide βA266-318 is shown to inhibit LPS binding and subsequent inflammatory events, having therapeutic implications to cure Gram-negative endotoxemia.

AB - Lipopolysaccharide (LPS), a bacterial endotoxin, triggers deleterious systemic inflammatory responses when released into blood circulation, causing organ dysfunction and death. In response to LPS stimulation, CD14 and toll-like receptor (TLR)-4 elicit inflammatory signaling cascades. Although leukocyte integrins (CD11b/CD18 and CD11c/CD18) were reported to bind LPS and induce NF-κB translocation, the evidence on such epitope location remains elusive. The present study aims to delineate the LPS-binding sites on the integrin CD18 antigen and to design peptide(s) as potential prophylactic and/or therapeutic agents to modulate LPS effects in activated Jurkat cells. Epitope mapping analysis using a series of CD18 truncated variants revealed two putative LPS-binding sites within the βA region (216-248 and 266-318 a.a.), which were further confirmed by point mutation studies. Inhibition assay demonstrated that the CD18-βA266-318 peptide could block LPS binding in a dosedependent manner. Our data also indicated that treatment with the CD18-peptide modulated TNF-α mRNA transcription via the NF-κB signaling pathway in LPS-activated Jurkat cells. In conclusion, we have identified two novel LPS-binding sites located at the CD18 βA domain of leukocyte integrin, and the integrin peptide βA266-318 is shown to inhibit LPS binding and subsequent inflammatory events, having therapeutic implications to cure Gram-negative endotoxemia.

KW - Endotoxin-neutralizing peptide

KW - Lipopolysaccharide

KW - NF-κB

KW - Prophylaxis

KW - Sepsis

KW - TNF-α

UR - http://www.scopus.com/inward/record.url?scp=35248867073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35248867073&partnerID=8YFLogxK

U2 - 10.1096/fj.06-7579com

DO - 10.1096/fj.06-7579com

M3 - Article

C2 - 17522381

AN - SCOPUS:35248867073

VL - 21

SP - 3231

EP - 3239

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 12

ER -